Stocks · News reference
Filed: 2026-08-27 AccNo: 0001140361-26-034698 Size: 302 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
argenx successfully completed its acquisition of Forte Biosciences for $77.00 per share in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The acquisition expands argenx's immunology portfolio and supports its Vision 2030 strategy to become a leading immunology innovation company by targeting diseases with limited treatment options.
Read original at globenewswire-incargenx announced a tender offer to acquire Forte Biosciences for $77 per share in cash. The acquisition adds Forte's first-in-class anti-CD122 monoclonal antibody FB102 to argenx's immunology pipeline. The tender offer commenced on August 6, 2026, with an expiration date of August 26, 2026, and is not subject to a financing condition. Forte's Board of Directors has recommended stockholders accept the offer.
Read original at globenewswire-incargenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. ("Purchaser"), a wholly-owned subsidiary of argenx BV ("argenx"), has commenced a
Read original at benzinga